ASCO Lung Cancer Highlights, Part 3: Immunotherapy for Stage III NSCLC by Dr. David Gerber
Article
Dr. David Gerber, University of Texas-Southwestern, reviews results of the START trial of tecemotide immunotherapy for stage III unresectable NSCLC.
[powerpress]